Impressively, combination treatment with PRMT5 and ATR inhibitors also showed more potent cytotoxicity on ATM-deficient MCL cells than those treated with either inhibitor alone, as indicated by the synergistic cytotoxic effects (Fig. 6b and Supplementary Fig. S5a). The gene discussed is PRMT5; the disease is mantle cell lymphoma.